Britain and America have finalized a key bilateral deal that will maintain zero import taxes on UK pharmaceutical shipments being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to boost spending on pharmaceuticals through the public health system. This commitment ensures that duties on these key products will remain at nothing for a timeframe of 36 months.
This deal is in response to earlier statements to dramatically increase duties on branded pharmaceutical products, with potential rates mentioned up to double the cost.
"This agreement with the Britain strengthens the international landscape for new treatments and brings long-overdue balance to American-British medicine commerce," an announcement declared.
Economic Significance
Drugs constitute one of the Britain's largest exports to the US, which is easily the largest destination for large British pharmaceutical firms.
Export figures reveal that in the 12 months prior to last September, the UK exported drugs worth over eleven billion pounds to the US. This amount accounted for a significant portion of British export trade in that span.
"This guarantee protects jobs, stimulates investment and facilitates the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary stated.
Key UK Commitments
The deal entails several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it judges new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to double overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage drug companies must return to the NHS to control costs will be restricted at fifteen percent. Previously, repayments topped 20%.
Recent Tensions
This agreement comes amid a protracted dispute between the sector and the ministers over spending levels and regulatory access.
This friction were exacerbated by claims that American consumers were charged several times more for the identical medicines than consumers in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar investments have been directed toward American operations.
The Science Minister acknowledged that the NHS must spend more on drugs, noting that its expenditure on drugs had declined as a proportion of its total funding over the previous ten-year period.
